SFC Fluidics
Private Company
Total funding raised: $5.5M
Overview
SFC Fluidics is a private medical device company leveraging proprietary microfluidic technology to create next-generation drug delivery systems. Its primary focus is the PANDA™ system, a patch pump for insulin delivery aimed at offering greater precision, safety, and convenience for diabetes patients. The company appears to be in a pre-revenue or early development stage, advancing its lead device while exploring broader applications of its platform. Leadership comprises a small, seasoned team with expertise in medical devices, microfluidics, and diabetes care.
Technology Platform
Proprietary microfluidic technology for precise, controlled drug delivery, enabling smaller, more accurate, and cost-effective devices like the PANDA insulin patch pump.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
The insulin pump market is highly competitive, dominated by large medtech companies like Insulet (Omnipod), Tandem Diabetes Care, and Medtronic, which offer integrated systems with continuous glucose monitors and automated insulin delivery algorithms. SFC Fluidics must differentiate on cost, form factor, or unique features to gain market share.